Cited by 298Estrogen and related hormone effectsProstate Cancer Treatment and ResearchBreast Cancer Treatment Studies

The DOI matches its Crossref record; 148 of the 152 references it cites were found in a registry or an index.

Minireview: The Androgen Receptor in Breast Tissues: Growth Inhibitor, Tumor Suppressor, Oncogene?

Open access

Hickey, T. E., Robinson, J. L. L., Carroll, J. S., Tilley, W. D.·2012·Molecular Endocrinology

DOI 10.1210/me.2012-1107PMC PMC3404296

Open this paper in CoChat — free account Open PDF

Abstract

Androgen receptor (AR) signaling exerts an antiestrogenic, growth-inhibitory influence in normal breast tissue, and this role may be sustained in estrogen receptor α (ERα)-positive luminal breast cancers. Conversely, AR signaling may promote growth of a subset of ERα-negative, AR-positive breast cancers with a molecular apocrine phenotype. Understanding the molecular mechanisms whereby androgens can elicit distinct gene expression programs and opposing proliferative responses in these two breast cancer phenotypes is critical to the development of new therapeutic strategies to target the AR in breast cancer.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1210/me.2012-1107

Cites

148 of 148 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Molecular portraits of human breast tumours
Perou, C., Sørlie, T., Eisen, M., van de Rijn, M., Jeffrey, S., Rees, C. A., Pollack, J., Ross, D., Johnsen, H., Akslen, L., et al. (2000) · Nature · doi:10.1038/35021093 · Cited by 16,551
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications
Sørlie, T., Perou, C. M., Tibshirani, R. J., Aas, T., Geisler, S. B., Johnsen, H., Hastie, T. J., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191367098 · Cited by 11,506
Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies
Lehmann, B. D., Bauer, J. A., Chen, X., Sanders, M. E., Chakravarthy, A. B., Shyr, Y., & Pietenpol, J. A. (2011) · Journal of Clinical Investigation · doi:10.1172/jci45014 · Cited by 5,592
Repeated observation of breast tumor subtypes in independent gene expression data sets
Sørlie, T., Tibshirani, R. J., Parker, J. S., Hastie, T. J., Marron, J. S., Nobel, A. B., Deng, S., Johnsen, H., Pesich, R., Geisler, S. B., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0932692100 · Cited by 5,508
A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes
Neve, R. M., Chin, K., Fridlyand, J., Yeh, J., Baehner, F. L., Fevr, T., Clark, L., Bayani, N., Coppé, J., Tong, F. K., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.10.008 · Cited by 3,224
Differential oestrogen receptor binding is associated with clinical outcome in breast cancer
Ross-Innes, C. S., Stark, R., Teschendorff, A. E., Holmes, K. A., Ali, H. R., Dunning, M., Brown, G. D., Gojiš, O., Ellis, I. O., Green, A. R., et al. (2012) · Nature · doi:10.1038/nature10730 · Cited by 2,182
Estrogen Carcinogenesis in Breast Cancer
Yager, J. D., & Davidson, N. E. (2006) · New England Journal of Medicine · doi:10.1056/nejmra050776 · Cited by 1,890
Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy
Rouzier, R., Perou, C. M., Symmans, W. F., Ibrahim, N. K., Cristofanilli, M., Anderson, K., Hess, K. R., Stec, J. J., Ayers, M., Wagner, P., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2421 · Cited by 1,889
Differential Oestrogen Receptor Binding is Associated with Clinical Outcome in Breast Cancer
Stark, R. (2012) · Lecture notes in computer science · doi:10.1007/978-3-642-29627-7_30 · Cited by 1,403
Sequence and Expression of Human Estrogen Receptor Complementary DNA
Greene, G. L., Gilna, P., Waterfield, M. D., BAKER, A. J., Hort, Y., & Shine, J. (1986) · Science · doi:10.1126/science.3753802 · Cited by 1,311

Flagged first, then by citations

Show all 152 references

4 of the 152 references couldn’t be matched to a known paper.

Sorted by citations

Cyclin D1 in Cancer: A Molecular Connection for Cell Cycle Control, Adhesion and Invasion in Tumor and Stroma
Montalto, F. I., & Amicis, F. D. (2020) · Cells · doi:10.3390/cells9122648 · Cited by 515
Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide
Cochrane, D. R., Bernales, S., Jacobsen, B. M., Cittelly, D. M., Howe, E. N., D’Amato, N. C., Spoelstra, N. S., Edgerton, S. M., Jean, A., Guerrero, J., et al. (2014) · Breast Cancer Research · doi:10.1186/bcr3599 · Cited by 427
A Hormone–DNA Repair Circuit Governs the Response to Genotoxic Insult
Goodwin, J. F., Schiewer, M. J., Dean, J. L., Schrecengost, R. S., de Leeuw, R., Han, S., Ma, T., Den, R. B., Dicker, A. P., Feng, F. Y.-C., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0108 · Cited by 366
A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1)
Bonnefoi, H. R., Grellety, T., Trédan, O., Saghatchian, M., Dalenc, F., Mailliez, A., L'Haridon, T., Cottu, P. H., Abadie‐Lacourtoisie, S., You, B., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw067 · Cited by 283
Progesterone and Breast Cancer
Trabert, B. L., Sherman, M. E., Kannan, N., & Stanczyk, F. Z. (2019) · Endocrine Reviews · doi:10.1210/endrev/bnz001 · Cited by 273
The androgen receptor is a tumor suppressor in estrogen receptor–positive breast cancer
Hickey, T. E., Selth, L. A., Chia, K. M., Laven‐Law, G., Milioli, H. H., Roden, D. L., Jindal, S., Hui, M. N., Finlay-Schultz, J., Ebrahimie, E., et al. (2021) · Nature Medicine · doi:10.1038/s41591-020-01168-7 · Cited by 261
Intracrine androgen biosynthesis, metabolism and action revisited
Schiffer, L., Arlt, W., & Storbeck, K.-H. (2018) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2017.08.016 · Cited by 217
“normal mammary gland and breast cancer, androgens and the expression of the AR have demonstrated both positive and negative outcomes in breast cancer as reviewed in (Hickey et al., 2012; McNamara and Sasano, 2015a, 2016).”
Androgen receptor (AR) differential roles in hormone-related tumors including prostate, bladder, kidney, lung, breast and liver
Chang, C., Lee, S. O., Yeh, S., & Chang, T. M. (2013) · Oncogene · doi:10.1038/onc.2013.274 · Cited by 214
Regulators of genetic risk of breast cancer identified by integrative network analysis
Castro, M. A. A., de Santiago, I., Campbell, T. M., Vaughn, C. M., Hickey, T. E., Ross, E. M., Tilley, W. D., Markowetz, F. M., Ponder, B. A. J., & Meyer, K. B. (2015) · Nature Genetics · doi:10.1038/ng.3458 · Cited by 195
Androgen receptor signaling in castration-resistant prostate cancer: a lesson in persistence
Coutinho, I., Day, T. K., Tilley, W. D., & Selth, L. A. (2016) · Endocrine Related Cancer · doi:10.1530/erc-16-0422 · Cited by 197
Cholesterol and Its Metabolites in Tumor Growth: Therapeutic Potential of Statins in Cancer Treatment
Chimento, A., Casaburi, I., Avena, P., Trotta, F., Luca, A. D., Rago, V., Pezzi, V., & Sirianni, R. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00807 · Cited by 189
Androgen Receptor (AR) Physiological Roles in Male and Female Reproductive Systems: Lessons Learned from AR-Knockout Mice Lacking AR in Selective Cells1
Chang, C., Lee, S. O., Wang, R.-S., Yeh, S., & Chang, T. (2013) · Biology of Reproduction · doi:10.1095/biolreprod.113.109132 · Cited by 170
Androgen Receptor in Breast Cancer—Clinical and Preclinical Research Insights
Anestis, A., Zoi, I., Papavassiliou, A. G., & Karamouzis, M. V. (2020) · Molecules · doi:10.3390/molecules25020358 · Cited by 157
Determinants of Receptor- and Tissue-Specific Actions in Androgen Signaling
Pihlajamaa, P., Sahu, B., & Jänne, O. A. (2015) · Endocrine Reviews · doi:10.1210/er.2015-1034 · Cited by 144
Androgen receptor phosphorylation: biological context and functional consequences
Koryakina, Y. A., Ta, H. Q., & Gioeli, D. G. (2014) · Endocrine Related Cancer · doi:10.1530/erc-13-0472 · Cited by 136
Complexities of androgen receptor signalling in breast cancer
McNamara, K. M., Moore, N. L. T., Hickey, T. E., Sasano, H., & Tilley, W. D. (2014) · Endocrine Related Cancer · doi:10.1530/erc-14-0243 · Cited by 134
Prognostic and predictive value of androgen receptor expression in postmenopausal women with estrogen receptor-positive breast cancer: results from the Breast International Group Trial 1–98
Kensler, K. H., Regan, M. M., Heng, Y. J., Baker, G. M., Pyle, M. E., Schnitt, S. J., Hazra, A., Kammler, R., Thurlimann, B. J. K., Colleoni, M. A., et al. (2019) · Breast Cancer Research · doi:10.1186/s13058-019-1118-z · Cited by 131
Prognostic value of androgen receptor in triple negative breast cancer: A meta-analysis
Wang, C., Pan, B., Zhu, H., Zhou, Y., Mao, F., Lin, Y., Xu, Q., & Sun, Q. (2016) · Oncotarget · doi:10.18632/oncotarget.10208 · Cited by 128
Androgen receptor positive triple negative breast cancer: Clinicopathologic, prognostic, and predictive features
Astvatsaturyan, K., Yue, Y., Walts, A. E., & Bose, S. (2018) · PLoS ONE · doi:10.1371/journal.pone.0197827 · Cited by 127
Androgen Receptor Biology in Triple Negative Breast Cancer: a Case for Classification as AR+ or Quadruple Negative Disease
Barton, V. N., D’Amato, N. C., Gordon, M. A., Christenson, J. L., ELIAS, A. D., & Richer, J. K. (2015) · Hormones and Cancer · doi:10.1007/s12672-015-0232-3 · Cited by 125
Deciphering the divergent roles of progestogens in breast cancer
Carroll, J. S., Hickey, T. E., Tarulli, G. A., Williams, M. R., & Tilley, W. D. (2016) · Nature reviews. Cancer · doi:10.1038/nrc.2016.116 · Cited by 126
The Role of the Androgen Receptor in Triple-Negative Breast Cancer
Shah, P. D., Gucalp, A., & Traina, T. A. (2013) · Women s Health · doi:10.2217/whe.13.33 · Cited by 121
Recent advances of therapeutic targets based on the molecular signature in breast cancer: genetic mutations and implications for current treatment paradigms
Lima, Z. S., Ghadamzadeh, M., Arashloo, F. T., Amjad, G., Ebadi, M. R., & Younesi, L. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0725-6 · Cited by 123
Estrogen receptor beta as a novel target of androgen receptor action in breast cancer cell lines
Rizza, P., Barone, I., Zito, D., Giordano, F., Lanzino, M., Amicis, F. D., Mauro, L., Sisci, D., Catalano, S., Wright, K. D., et al. (2014) · Breast Cancer Research · doi:10.1186/bcr3619 · Cited by 114
Extranuclear Steroid Receptors Are Essential for Steroid Hormone Actions
Levin, E. R. (2015) · Annual Review of Medicine · doi:10.1146/annurev-med-050913-021703 · Cited by 112
AR collaborates with ERα in aromatase inhibitor-resistant breast cancer
Rechoum, Y., Rovito, D., Iacopetta, D., Barone, I., Andò, S., Weigel, N. L., O’Malley, B. W., Brown, P. H., & Fuqua, S. A. W. (2014) · Breast Cancer Research and Treatment · doi:10.1007/s10549-014-3082-8 · Cited by 109
Androgens Induce Invasiveness of Triple Negative Breast Cancer Cells Through AR/Src/PI3-K Complex Assembly
Giovannelli, P., Donato, M. D., Auricchio, F., Castoria, G., & Migliaccio, A. (2019) · Scientific Reports · doi:10.1038/s41598-019-41016-4 · Cited by 109
The dual regulatory role of miR-204 in cancer
Li, T., Pan, H., & Li, R. (2016) · Tumor Biology · doi:10.1007/s13277-016-5144-5 · Cited by 107
Prognostic significance of androgen receptor expression in invasive breast cancer: transcriptomic and protein expression analysis
Aleskandarany, M. A., Abduljabbar, R. F., Ashankyty, I., Elmouna, A., Jerjees, D. A., Ali, S., Buluwela, L., Diez, M., Caldas, C., Green, A. R., et al. (2016) · Breast Cancer Research and Treatment · doi:10.1007/s10549-016-3934-5 · Cited by 101
Apocrine carcinoma of the breast: a comprehensive review.
Vranić, S., Schmitt, F. C., Sapino, A., Costa, J. L., Reddy, S. B., Castro, M. P., & Gatalica, Z. (2013) · PubMed · doi:10.14670/hh-28.1393 · Cited by 100
Expression of androgen receptor splice variants in clinical breast cancers
Hickey, T. E., Irvine, C. M., Dvinge, H., Tarulli, G. A., Hanson, A. R., Ryan, N. K., Pickering, M. A., Birrell, S. N., Hu, D. G., Mackenzie, P. I., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.6296 · Cited by 99
Role of the androgen receptor in triple-negative breast cancer.
Rampurwala, M. M., Wisinski, K. B., & O'Regan, R. M. (2016) · PubMed · Cited by 97
EJE PRIZE 2016: Mechanisms of oestrogen receptor (ER) gene regulation in breast cancer
Carroll, J. S. (2016) · European Journal of Endocrinology · doi:10.1530/eje-16-0124 · Cited by 96
Androgen Receptor Status Is a Prognostic Marker in Non-Basal Triple Negative Breast Cancers and Determines Novel Therapeutic Options
Gasparini, P., Fassan, M., Cascione, L., Güler, G., Balcı, S., Irkkan, Ç., Paisie, C. A., Lovat, F., Morris, Q., Zhang, J., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0088525 · Cited by 92
Premenopausal serum sex hormone levels in relation to breast cancer risk, overall and by hormone receptor status-Results from the EPIC cohort
Kaaks, R., Tikk, K., Sookthai, D., Schöck, H., Johnson, T., Tjønneland, A. M., Olsen, A., Overvad, K., Clavel‐Chapelon, F., Dossus, L., et al. (2013) · International Journal of Cancer · doi:10.1002/ijc.28528 · Cited by 92
Androgen Receptor Expression in Early Triple-Negative Breast Cancer: Clinical Significance and Prognostic Associations
Pistelli, M., Caramanti, M., Biscotti, T., Santinelli, A., Pagliacci, A., Lisa, M. D., Ballatore, Z., Ridolfi, F., Maccaroni, E., Bracci, R., et al. (2014) · Cancers · doi:10.3390/cancers6031351 · Cited by 88
The Magnitude of Androgen Receptor Positivity in Breast Cancer Is Critical for Reliable Prediction of Disease Outcome
Ricciardelli, C., Bianco‐Miotto, T., Jindal, S., Butler, L. M., Leung, S. C. Y., McNeil, C. M., O'Toole, S. A., Ebrahimie, E., Millar, E. K. A., Sakko, A. J., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1199 · Cited by 85
A combination of GATA3 and SOX10 is useful for the diagnosis of metastatic triple-negative breast cancer
Tozbikian, G. H., & Zynger, D. L. (2018) · Human Pathology · doi:10.1016/j.humpath.2018.11.005 · Cited by 82
Endocrine disruption of oestrogen action and female reproductive tract cancers
Gibson, D. A., & Saunders, P. T. K. (2013) · Endocrine Related Cancer · doi:10.1530/erc-13-0342 · Cited by 83
Androgen receptor function and targeted therapeutics across breast cancer subtypes
Kolyvas, E. A., Caldas, C., Kelly, K., & Ahmad, S. S. (2022) · Breast Cancer Research · doi:10.1186/s13058-022-01574-4 · Cited by 80
Progesterone and Overlooked Endocrine Pathways in Breast Cancer Pathogenesis
Brisken, C., Hess, K. P., & Marcone, R. (2015) · Endocrinology · doi:10.1210/en.2015-1392 · Cited by 84
Combined Androgen and Estrogen Receptor Status in Breast Cancer: Treatment Prediction and Prognosis in a Population-Based Prospective Cohort
Elebro, K., Borgquist, S., Simonsson, M., Markkula, A., Jirström, K., Ingvar, C., Rose, C., & Jernström, H. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2564 · Cited by 78
Complete Response of Metastatic Androgen Receptor–Positive Breast Cancer to Bicalutamide: Case Report and Review of the Literature
Arce-Salinas, C., Martínez, M. C. R., Hanna, W. M., Bedard, P. L., & Warner, E. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.8899 · Cited by 77
Differential Regulation of Estrogen Receptor α Expression in Breast Cancer Cells by Metastasis-Associated Protein 1
Kang, H., Lee, M.-H., Kang, H.-L., Kim, S.-H., Ahn, J.-R., Na, H., Na, T., Kim, Y. N., Seong, J. K., & Lee, M. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2020 · Cited by 76
A bi-faceted role of estrogen receptor β in breast cancer
Leygue, E., & Murphy, L. C. (2013) · Endocrine Related Cancer · doi:10.1530/erc-12-0389 · Cited by 74
Identification of Androgen Receptor Splice Variant Transcripts in Breast Cancer Cell Lines and Human Tissues
Hu, D. G., Hickey, T. E., Irvine, C. M., Wijayakumara, D., Lu, L., Tilley, W. D., Selth, L. A., & Mackenzie, P. I. (2014) · Hormones and Cancer · doi:10.1007/s12672-014-0171-4 · Cited by 75
The Divergent Function of Androgen Receptor in Breast Cancer; Analysis of Steroid Mediators and Tumor Intracrinology
Bleach, R., & McIlroy, M. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00594 · Cited by 71
The intracrinology of breast cancer
McNamara, K. M., & Sasano, H. (2014) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2014.04.004 · Cited by 70
Increased androgen receptor activity and cell proliferation in aromatase inhibitor-resistant breast carcinoma
Fujii, R., Hanamura, T., Suzuki, T., Gohno, T., Shibahara, Y., Niwa, T., Yamaguchi, Y., Ohnuki, K., Kakugawa, Y., Hirakawa, H., et al. (2014) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2014.08.019 · Cited by 67
Testosterone and breast cancer prevention
Glaser, R. L., & Dimitrakakis, C. (2015) · Maturitas · doi:10.1016/j.maturitas.2015.06.002 · Cited by 66
Androgen Receptor Expression and Breast Cancer Survival: Results From the Nurses’ Health Studies
Kensler, K. H., Poole, E. M., Heng, Y. J., Collins, L. C., Glass, B., Beck, A. H., Hazra, A., ROSNER, B. A., Eliassen, A. H., Hankinson, S. E., et al. (2018) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djy173 · Cited by 66
Interdisciplinary Management of Transgender Individuals at Risk for Breast Cancer: Case Reports and Review of the Literature
Eismann, J., Heng, Y. J., Fleischmann-Rose, K., Tobias, A. M., Phillips, J., Wulf, G. M., & Kansal, K. J. (2018) · Clinical Breast Cancer · doi:10.1016/j.clbc.2018.11.007 · Cited by 64
Androgen receptor expression predicts different clinical outcomes for breast cancer patients stratified by hormone receptor status
Jiang, H.-S., Kuang, X.-Y., Sun, W.-L., Xu, Y., Zheng, Y.-Z., Liu, Y., Lang, G., Qiao, F., Hu, X., & Shao, Z. (2016) · Oncotarget · doi:10.18632/oncotarget.9778 · Cited by 64
Prognostic Significance of Androgen Receptor Expression in Triple Negative Breast Cancer: A Systematic Review and Meta-Analysis
Xu, M., Yuan, Y., Yan, P., Jiang, J., Ma, P., Niu, X., Ma, S., Cai, H., & Yang, K. (2020) · Clinical Breast Cancer · doi:10.1016/j.clbc.2020.01.002 · Cited by 64
Targeting the androgen receptor in triple-negative breast cancer: current perspectives
Mina, A. A., Yoder, R., & Sharma, P. (2017) · OncoTargets and Therapy · doi:10.2147/ott.s126051 · Cited by 63
Preclinical evaluation of the AR inhibitor enzalutamide in triple-negative breast cancer cells
Caiazza, F., Murray, A. M., Madden, S. F., Synnott, N. C., Ryan, E. J., O’Donovan, N., Crown, J. P., & Duffy, M. J. (2016) · Endocrine Related Cancer · doi:10.1530/erc-16-0068 · Cited by 63
Hormone receptors as a marker of poor survival in epithelial ovarian cancer
van Kruchten, M., van der Marel, P., de Munck, L., Hollema, H., Arts, H. J. G., Timmer‐Bosscha, H., de Vries, E. G. E., Hospers, G. A. P., & Reyners, A. K. L. (2015) · Gynecologic Oncology · doi:10.1016/j.ygyno.2015.06.032 · Cited by 60
Testosterone therapy in women: Myths and misconceptions
Glaser, R. L., & Dimitrakakis, C. (2013) · Maturitas · doi:10.1016/j.maturitas.2013.01.003 · Cited by 62
Metformin Decreases Circulating Androgen and Estrogen Levels in Nondiabetic Women With Breast Cancer
Campagnoli, C., Berrino, F., Venturelli, E., Abbà, C., Biglia, N., Brucato, T., Cogliati, P., Danese, S., Donadio, M., Zito, G., et al. (2013) · Clinical Breast Cancer · doi:10.1016/j.clbc.2013.08.012 · Cited by 59
Androgen and Estrogen Receptors in Breast Cancer Coregulate Human UDP-Glucuronosyltransferases 2B15 and 2B17
Hu, D. G., Selth, L. A., Tarulli, G. A., Meech, R., Wijayakumara, D., Chanawong, A., Russell, R., Caldas, C., Robinson, J. L. L., Carroll, J. S., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-3372 · Cited by 59
Reduced breast cancer incidence in women treated with subcutaneous testosterone, or testosterone with anastrozole: A prospective, observational study
Glaser, R. L., & Dimitrakakis, C. (2013) · Maturitas · doi:10.1016/j.maturitas.2013.08.002 · Cited by 58
Phospho-kinase profile of triple negative breast cancer and androgen receptor signaling
Cuenca-López, M. D., Montero, J. C., Morales, J. C., Prat, A., Pandiella, A., & Ocaña, A. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-302 · Cited by 60
MicroRNA‐135b regulates ERα, AR and HIF1AN and affects breast and prostate cancer cell growth
Aakula, A., Leivonen, S., Hintsanen, P., Aittokallio, T. A., Ceder, Y., Børresen‐Dale, A., Perälä, M., Östling, P., & Kallioniemi, O. (2015) · Molecular Oncology · doi:10.1016/j.molonc.2015.03.001 · Cited by 57
HER2 is not a cancer subtype but rather a pan-cancer event and is highly enriched in AR-driven breast tumors
Daemen, A., & Manning, G. (2018) · Breast Cancer Research · doi:10.1186/s13058-018-0933-y · Cited by 56
Nucleic-Acid-Based Targeted Degradation in Drug Discovery
Wang, W., He, S., Dong, G., & Sheng, C. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00875 · Cited by 56
Novel therapeutic avenues in triple-negative breast cancer: PI3K/AKT inhibition, androgen receptor blockade, and beyond
Chan, J. J., Tan, T. J., & Dent, R. A. (2019) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835919880429 · Cited by 54
Androgen excess in breast cancer development: implications for prevention and treatment
Secreto, G., Girombelli, A., & Krogh, V. (2018) · Endocrine Related Cancer · doi:10.1530/erc-18-0429 · Cited by 53
A Tale of Two Signals: AR and WNT in Development and Tumorigenesis of Prostate and Mammary Gland
Pakula, H., Xiang, D., & Li, Z. (2017) · Cancers · doi:10.3390/cancers9020014 · Cited by 55
Androgen receptor: A promising therapeutic target in breast cancer
Vasiliou, S. K., & Diamandis, E. P. (2019) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408363.2019.1575643 · Cited by 52
Tissue control of androgen action: The ups and downs of androgen receptor expression
Hunter, I., Hay, C. W., Eßwein, B., Watt, K., & McEwan, I. J. (2017) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2017.08.002 · Cited by 52
Androgen Receptor in Breast Cancer: From Bench to Bedside
Chen, M., Yang, Y., Xu, K., Li, L., Huang, J., & Qiu, F. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00573 · Cited by 49
Is androgen receptor targeting an emerging treatment strategy for triple negative breast cancer?
Anestis, A., Karamouzis, M. V., Dalagiorgou, G., & Papavassiliou, A. G. (2015) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2015.04.009 · Cited by 46
Hormonal modulation of ESR1 mutant metastasis
Gu, G., Tian, L. H., Herzog, S. K., Rechoum, Y., Gelsomino, L., Gao, M., Du, L., Kim, J.-A., Dustin, D. J., Lo, H. C., et al. (2020) · Oncogene · doi:10.1038/s41388-020-01563-x · Cited by 46
Breast Cancer: Targeting of Steroid Hormones in Cancerogenesis and Diagnostics
Valko-Rokytovská, M., Očenáš, P., Salayová, A., & Kostecká, Z. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115878 · Cited by 44
Non-canonical AR activity facilitates endocrine resistance in breast cancer
Chia, K., Milioli, H. H., Portman, N., Laven‐Law, G., Coulson, R. S., Yong, A., Segara, D., Parker, A., Caldon, C. E., Deng, N., et al. (2018) · Endocrine Related Cancer · doi:10.1530/erc-18-0333 · Cited by 42
Androgen Receptor Immunohistochemistry as a Companion Diagnostic Approach to Predict Clinical Response to Enzalutamide in Triple-Negative Breast Cancer
Kumar, V., Yu, J., Phan, V. T., Tudor, I. C., Peterson, A., & Uppal, H. (2017) · JCO Precision Oncology · doi:10.1200/po.17.00075 · Cited by 42
Postmenopausal breast cancer, androgens, and aromatase inhibitors
Campagnoli, C., Pasanisi, P., Castellano, I., Abbà, C., Brucato, T., & Berrino, F. (2013) · Breast Cancer Research and Treatment · doi:10.1007/s10549-013-2505-2 · Cited by 39
Androgenic pathways in the progression of triple-negative breast carcinoma: a comparison between aggressive and non-aggressive subtypes
McNamara, K. M., Yoda, T., Nurani, A. M., Shibahara, Y., Miki, Y., Wang, L., Nakamura, Y., Suzuki, K., Yang, Y., Abe, E., et al. (2014) · Breast Cancer Research and Treatment · doi:10.1007/s10549-014-2942-6 · Cited by 39
Targeted radiosensitization with PARP1 inhibition: optimization of therapy and identification of biomarkers of response in breast cancer
Feng, F. Y.-C., Speers, C. W., Liu, M., Jackson, W., Moon, D. H., Rinkinen, J. R., Wilder-Romans, K., Jagsi, R., & Pierce, L. J. (2014) · Breast Cancer Research and Treatment · doi:10.1007/s10549-014-3085-5 · Cited by 39
Pushing estrogen receptor around in breast cancer
Lim, E., Tarulli, G. A., Portman, N., Hickey, T. E., Tilley, W. D., & Palmieri, C. (2016) · Endocrine Related Cancer · doi:10.1530/erc-16-0427 · Cited by 40
Steroid metabolism in breast cancer: Where are we and what are we missing?
Africander, D., & Storbeck, K. (2017) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2017.05.016 · Cited by 40
Quadruple-negative breast cancer: novel implications for a new disease
Bhattarai, S., Saini, G., Gogineni, K., & Aneja, R. (2020) · Breast Cancer Research · doi:10.1186/s13058-020-01369-5 · Cited by 40
Revisiting Androgen Receptor Signaling in Breast Cancer
Dai, C. S., & Ellisen, L. W. (2023) · The Oncologist · doi:10.1093/oncolo/oyad049 · Cited by 38
The convergence of DNA damage checkpoint pathways and androgen receptor signaling in prostate cancer
Ta, H. Q., & Gioeli, D. G. (2014) · Endocrine Related Cancer · doi:10.1530/erc-14-0217 · Cited by 37
Up-regulated expression of scavenger receptor class B type 1 (SR-B1) is associated with malignant behaviors and poor prognosis of breast cancer
Li, J., Wang, J., Li, M., Yin, L., Li, X., & Zhang, T.-G. (2016) · Pathology - Research and Practice · doi:10.1016/j.prp.2016.03.011 · Cited by 37
Influence of stromal–epithelial interactions on androgen action
Nieto, C., Rider, L. C., & Cramer, S. D. (2014) · Endocrine Related Cancer · doi:10.1530/erc-14-0138 · Cited by 40
The molecular consequences of androgen activity in the human breast
Raths, F., Karimzadeh, M., Ing, N., Martinez, A., Yang, Y., Qu, Y., Lee, T.-Y., Mulligan, B., Devkota, S., Tilley, W. T., et al. (2023) · Cell Genomics · doi:10.1016/j.xgen.2023.100272 · Cited by 39
Differences in the Transcriptional Response to Fulvestrant and Estrogen Deprivation in ER-Positive Breast Cancer
Patani, N., Dunbier, A. K., Anderson, H., Ghazoui, Z. F., Ribas, R., Anderson, E., Gao, Q., A’Hern, R., Mackay, A. G., Lindemann, J. P. O., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1378 · Cited by 34
Selective androgen receptor modulators as improved androgen therapy for advanced breast cancer
Coss, C. C., Jones, A. J., & Dalton, J. T. (2014) · Steroids · doi:10.1016/j.steroids.2014.06.010 · Cited by 34
Bringing androgens up a NOTCH in breast cancer
Tarulli, G. A., Butler, L. M., Tilley, W. D., & Hickey, T. E. (2014) · Endocrine Related Cancer · doi:10.1530/erc-14-0248 · Cited by 34
The androgen receptor as a surrogate marker for molecular apocrine breast cancer subtyping
Lakis, S., Kotoula, V., Eleftheraki, A. G., Batistatou, A. K., Bobos, M., Κoletsa, T., Timotheadou, E. T., Chrisafi, S., Pentheroudakis, G. E., Koutras, A. K., et al. (2014) · The Breast · doi:10.1016/j.breast.2014.02.013 · Cited by 33
Harnessing a Different Dependency: How to Identify and Target Androgen Receptor-Positive Versus Quadruple-Negative Breast Cancer
Christenson, J. L., Trepel, J. B., Ali, H. Y., Lee, S., Eisner, J. R., Baskin-Bey, E. S., ELIAS, A. D., & Richer, J. K. (2018) · Hormones and Cancer · doi:10.1007/s12672-017-0314-5 · Cited by 34
Long non-coding RNA regulating androgen receptor signaling in breast and prostate cancer
Kumar, S., Prajapati, K. S., Singh, A. K., Kushwaha, P. P., Shuaib, M., & Gupta, S. (2021) · Cancer Letters · doi:10.1016/j.canlet.2020.11.039 · Cited by 32
The efficacy and safety of enzalutamide with trastuzumab in patients with HER2+ and androgen receptor-positive metastatic or locally advanced breast cancer
Wardley, A. M., Cortés, J., Provencher, L., Miller, K. D., Chien, A. J., Rugo, H. S., Steinberg, J., Sugg, J. E., Tudor, I. C., Huizing, M. T., et al. (2021) · Breast Cancer Research and Treatment · doi:10.1007/s10549-021-06109-7 · Cited by 31
Breast cancer subtype dictates DNA methylation and ALDH1A3-mediated expression of tumor suppressor RARRES1
Coyle, K. M., Murphy, J. P., Vidovic, D., Vaghar-Kashani, A., Dean, C. A., Sultan, M., Clements, D. R., Wallace, M., Thomas, M. L., Hundert, A. S., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.9858 · Cited by 31
7-Substituted umbelliferone derivatives as androgen receptor antagonists for the potential treatment of prostate and breast cancer
Kandil, S., Westwell, A. D., & McGuigan, C. (2016) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2016.02.088 · Cited by 31
Effects of ospemifene, a novel selective estrogen-receptor modulator, on human breast tissue ex vivo
Eigėlienė, N., Kangas, L., Hellmer, C., Kauko, T., Erkkola, R., & Härkönen, P. L. (2016) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0000000000000624 · Cited by 30
Androgen Receptor Protein Levels Are Significantly Reduced in Serous Ovarian Carcinomas Compared with Benign or Borderline Disease but Are Not altered by Cancer Stage or Metastatic Progression
Butler, M. S., Ricciardelli, C., Tilley, W. D., & Hickey, T. E. (2013) · Hormones and Cancer · doi:10.1007/s12672-013-0135-0 · Cited by 29
A simple and reproducible prognostic index in luminal ER-positive breast cancers
Castellano, I., Chiusa, L., Vandone, A. M., Beatrice, S., Goia, M., Donadio, M., Arisio, R., Muscarà, F., Durando, A., Viale, G., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt183 · Cited by 29
Clinical significance of serum PSA in breast cancer patients
Hanamura, T., Ohno, K., Hokibara, S., Murasawa, H., Nakamura, T., Watanabe, H., Kaizuka, M., Sawano, S., Koyama, H., & Ito, K. (2019) · BMC Cancer · doi:10.1186/s12885-019-6256-2 · Cited by 28

Authors: Hickey, T. E., Robinson, J. L. L., Carroll, J. S., & Tilley, W. D.
Affiliations: Hanson Institute (AU)
University of Cambridge (GB)
Corresponding author: Tilley, W. D.
ORCID: Hickey, T. E.
Robinson, J. L. L.
Carroll, J. S.
Tilley, W. D.
Venue: Molecular Endocrinology
Publisher: The Endocrine Society
Published: 2012-08-01
Volume: 26
Issue: 8
Pages: 1252-1267
ISSN: 0888-8809 (ISSN-L)
1944-9917
DOI: 10.1210/me.2012-1107
PMC: PMC3404296
OpenAlex: W1974738527
Cited by: 289
References: 152
Citations by year: 2026: 10 · 2025: 12 · 2024: 15 · 2023: 11 · 2022: 15 · 2021: 40 · 2020: 16 · 2019: 19 · 2018: 27 · 2017: 18 · 2016: 29 · 2015: 22 · 2014: 30 · 2013: 24 · 2012: 1
FWCI: 3.06
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: Molecular Endocrinology (publishedVersion)
Europe PMC (PubMed Central) (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Adelaide Research & Scholarship (AR&S) (University of Adelaide) (submittedVersion)
Funders: U.S. Department of Defense (W81XWH-11-1-, W81XWH)
European Molecular Biology Organization
Cancer Research UK
University of Cambridge
National Breast Cancer Foundation
Medical Research Council
National Health and Medical Research Council (1008349)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
Keywords: androgen receptor, breast cancer, estrogen receptor alpha, luminal breast cancer, apocrine breast cancer, tumor suppressor, oncogenes, androgen signaling, transcriptional programs, therapeutic targeting
MeSH terms: Androgens, Animals, Breast Neoplasms, Female, Growth Inhibitors, Humans, Oncogenes, Receptors, Androgen, Signal Transduction, Genes, Tumor Suppressor, Mammary Glands, Human, Estrogen Receptor alpha

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Minireview: The Androgen Receptor in Breast Tissues: Growth Inhibitor, Tumor Suppressor, Oncogene?

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks